Search Medical Condition
Please enter condition
Please choose location from dropdown

Psychosis Clinical Trials

A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1006) clinical trials

A Randomized, Open-label, Multiple-dose, Parallel Design, Comparative Bioequivalence Study of Paliperidone Palmitate Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus Invega Sustenna® (paliperidone palmitate) Extended-Release Injectable Suspension (156mg/1.0 mL) in Schizophrenia Patients Already Stabilized on Paliperidone Palmitate

Phase N/A

INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, FIXED-DOSE STUDY OF Lu AF35700 IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA

Phase

The purpose of this study is to test the safety of GW8556553 (the study drug) and how well it works at different doses. We are doing this study in patients with depression (Major Depressive Disorder) to find out: 1. What are the effects of the drug, good or bad? 2. ...

Phase

Study Description: The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. ...

Phase

People who may develop Alzheimer's Disease are asked to participate in a research study being conducted by New York University School of Medicine.

Phase N/A

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia. May be compensated for time and ...

Phase

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.

Phase

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511

Phase

Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia   Other Details:  https://clinicaltrials.gov/ct2/show/study/NCT02783573

Phase

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).

Phase